Introduction
Design | Outcomes | Comments | ||||||
---|---|---|---|---|---|---|---|---|
Short-term (4–9 days post) | Long-term (3–6 weeks post) | |||||||
Study | Design | Population | Regimens | Clin | Bact | Clin | Bact | |
Cronberg 2001 [20] | Placebo-controlled RCT | men: 42%; median age: | Norfloxacin 400 mg bid po, 10 days (n = 83) | 96.0 | 89.0 | 84.0* | after cefuroxime 0.75–1.5 g tid iv 2–4 days | |
women: 55y (19–90), | Ceftibuten 200 mg bid po, 10 days (n = 85) | 89.0 | 75.0 | 63.0* | ||||
men: 68y (23–90) | ||||||||
Fang 1991 [35] | Open label RCT | Mean age (range): | Ciprofloxacin 500 mg bid po, 7–10 days (n = 37) | 81.0 | 63.0 | 69.0 | 21.0 | 51% indwelling urinary catheter, 100% urinary tract abnormality |
72y (20–95); men: 97% | Aminoglycoside 1–1.7 mg/kg tid 7–10 days (n = 28) | 82.0 | 15.0 | 58.0 | 23.0 | |||
Klausner 2007 [18] | Placebo-controlled RCT | Mean age ± SD: 39 ± 17y | Levofloxacin 750 mg od po, 5 days (n = 146) | 93.8a
| 91.3a
| 92.5a
| 92.5a
| 6%–7% initially iv treatment (levofloxacin or ciprofloxacin) |
men: 4% | Ciprofloxacin 500 mg bid po, 10 days (n = 165) | 88.2a
| 86.8a
| 89.5a
| 93.4a
| |||
Mombelli 1999 [32] | Open label RCT | Median age: 66y (18–96); men: 41% | Ciprofloxacin 500 mg bid po, duration ns (n = 72) | 95.8 | 97.2 | NS | NS | 29.8% comorbidity; 23% postmenopausal women |
Ciprofloxacin 200 mg bid iv, duration ns (n = 69) | 97.1 | 98.6 | NS | NS | ||||
van Nieuwkoop 2010 [33] | Prospective observational cohort study | Median age [IQR]: | Ciprofloxacin 500 mg bid po, 10–14 days (n = 146) | NS | NS | 90.0 | NS | - outpatient treatment |
63y [43–77]; men: 34% | Cefuroxime ± gentamicin 2–4 days → | NS | NS | 89.0 | NS | - initially hospitalized, then first choice ciprofloxacin po | ||
ciprofloxacin 500 mg bid po, 6–12 days (n = 242) | ||||||||
Richard 1998 [21] | Placebo-controlled and open label RCT | Mean age (range): | Levofloxacin 250 mg od po, 7–10 days (n = 89) | 93.2 | 94.4 | NS | 87.3 | |
41y (18–91); men: 13% | Ciprofloxacin 500 mg bid po, 10 days (n = 58) | 94.8 | 93.8 | NS | 93.5 | |||
Lomefloxacin 400 mg od po, 14 days (n = 39) | 94.9 | 93.8 | NS | 93.5 | ||||
Sandberg 1990 [24] | Placebo-controlled RCT | Mean age (range): | Norfloxacin 400 mg bid po, 14 days (n = 99) | 97.0 | 98.0 | 88.0 | 87.0b
| 25% “complicated” |
50y (16–87); men:25% | Cefadroxil 1 g bid po, 14 days (n = 98) | 97.0 | 65.0 | 47.0 | 48.0b
| |||
Stamm 1987 [15] | Open label RCT | Median age: NS (pre- and postmenopausal); | Ampicillin 2 g od, 2 weeks (n = 17) | NS | NS | 64.7* | febrile UTI, 65% of subjects | |
Ampicillin 2 g od, 6 weeks (n = 10) | NS | NS | 40.0* | |||||
men: 0% | TMP/SMX 160/800 mg bid, 2 weeks (n = 21) | NS | NS | 90.5* | ||||
TMP/SMX 160/800 mg bid, 6 weeks (n = 12) | NS | NS | 83.3* | |||||
Talan 2000 [17] | Placebo-controlled RCT | Median age: 24y (18–58) | Ciprofloxacin 500 mg bid po, 7 days (n = 128) | 96.5 | 99.1 | 90.6 | 84.7 | 15 once 400 mg cipro iv |
men: 0% | TMP/SMX 160/800 mg bid po, 14 days (n = 127) | 82.9 | 89.1 | 77.4 | 74.1 | 26 once ceftriaxon 1 g iv | ||
Ulleryd 2003 [31] | Open label RCT | Median age: 62y (18–85) | Ciprofloxacin 500 mg bid po, 2 weeks (n = 38) | 92.0 | 89.0 | 83.0 | 75.0 | |
men: 100% | Ciprofloxacin 500 mg bid po, 4 weeks (n = 34) | 97.0 | 97.0 | 88.0 | 85.0 |